Results 11 to 20 of about 2,379 (179)
Impact of Pharmacy Services on Time to Elexacaftor-Tezacaftor-Ivacaftor Initiation [PDF]
Journal of Managed Care & Specialty Pharmacy, 2021 The approval of elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) expanded highly effective cystic fibrosis transmembrane receptor modulator therapy to approximately 90% of persons age 12 and older with cystic fibrosis. Clinical pharmacists and pharmacy technicians played a key role in planning for ELX/TEZ/IVA initiation prior to FDA approval as well as ...
Lauren Roder +4 more
openaire +2 more sources
Pulmonary Therapy, 2020 Introduction The triple-combination (TC) cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen elexacaftor, tezacaftor, and ivacaftor was shown to be safe and efficacious in phase 3 trials of people with cystic fibrosis (pwCF) ≥ 12
Alice Tsai +6 more
doaj +1 more source
Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis
Medicina, 2022 Triple-combination therapy with elexacaftor, tezacaftor and ivacaftor has been recently approved for cystic fibrosis patients with at least one F508del mutation in the transmembrane conductance regulator of the cystic fibrosis gene.
Federica Li Pomi +8 more
doaj +1 more source
Journal of Patient Experience, 2021 Cystic fibrosis (CF) is the leading genetic disease among Caucasians; however, advances in diagnosis and treatment have improved both quality and quantity of life for those affected.
Sigrid Ladores PhD, RN, PNP, CNE, FAAN +1 more
doaj +1 more source
Aplasia Cutis Congenita in the Setting of Maternal Cystic Fibrosis
Annals of Internal Medicine: Clinical Cases, 2022 Aplasia cutis congenita is a rare scalp defect. An affected neonate was delivered after in utero exposure beginning in the midtrimester to elexacaftor/tezacaftor/ivacaftor for maternal cystic fibrosis management. Although aplasia cutis congenita has many
Govind Kallumkal, Robert Egerman
doaj +1 more source
The Effect of Elexacaftor/Tezacaftor/Ivacaftor on Hospitalizations and Intravenous Antibiotic Use
The Permanente Journal, 2022 Elexacaftor/tezacaftor/ivacaftor (ETI) is a highly effective cystic fibrosis transmembrane conductance regulator modulator. It has been shown to improve lung function and decrease pulmonary exacerbations in short-term clinical trials. The effect of ETI on hospitalization and intravenous (IV) antibiotic rates is not known.
Eric, Walter, Jennifer L, Bass
openaire +2 more sources
Novel reaction to new cystic fibrosis medication Trikafta
Clinical Case Reports, 2021 We present a novel case of an urticaria multiforme‐type drug reaction to the new cystic fibrosis medication Trikafta (elexacaftor + tezacaftor + ivacaftor).
Julian Stashower +3 more
doaj +1 more source
Impact of Elexacaftor–Tezacaftor–Ivacaftor on lung disease in cystic fibrosis
Pediatric Pulmonology, 2023 AbstractBackgroundIn people with cystic fibrosis (pwCF), the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, such as Elexacaftor–Tezacaftor–Ivacaftor (ETI), on structural changes in the lungs is unclear.ObjectiveTo determine the impact of ETI on clinical parameters and on structural lung disease as measured by ...
Courtney Gushue +6 more
openaire +2 more sources
Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)
Canadian Journal of Health Technologies, 2021 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +3 more sources
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
European Respiratory Review, 2020 Drug compounds that augment the production and activity of the cystic fibrosis (CF) transmembrane regulator (CFTR) have revolutionised CF care. Many adults and some children with CF suffer advanced and severe lung disease or await lung transplantation ...
Michal Shteinberg +1 more
doaj +1 more source